Metavia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on their pipeline targeting obesity and MASH with next-generation therapeutics. Key highlights include the development of DA-1726, a novel GLP1R/GCGR dual agonist for obesity, which has shown no treatment-related discontinuations and mild gastrointestinal events in Phase 1 trials. The company also shared promising results from DA-1241 for MASH, which met its primary endpoint and demonstrated direct hepatic effects in Phase 2a trials. Metavia plans to pursue further studies and regulatory milestones in the coming years. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.